$PSNL 0.62 Developing
- Date
- Jul 20, 2026
- Mentions
- 2
- Unique authors
- 2
- Sector
- biotech
- Stance
- neutral
- On card
- no
Sentiment history
No sentiment history available for $PSNL yet.
Sentiment
Notable posts
-
neutral 241 eng
$TEM is acquiring $PSNL for $1.5B adding its NeXT Personal MRD technology to expand deeper into cancer recurrence monitoring. Personalis shareholders will receive $16.25 per share with the deal structured as all stock but allowing Tempus to pay up to 50% in cash. https://t.co/1cGhr0PhJX
view on X → -
neutral 157 eng
Tempus AI $TEM to ACQUIRE Personalis $PSNL for $1.5 billion, expanding deeper into cancer recurrence monitoring Personalis shareholders will receive $16.25 per share, a 6% premium to the latest close and a 28% premium to the unaffected 30-day average. The deal brings Personalis’ NeXT Personal MRD technology into Tempus’ AI and clinical data platform, strengthening its position across cancer diagnosis, treatment selection, and recurrence monitoring. The transaction is structured as an all-stock deal, though Tempus can pay up to 50% in cash.
view on X →
Only one day of history so far — the signal arc fills in as the daily job runs.